ACTRN12620000850976尚未招募未知
A phase II randomised controlled clinical trial in patients with acute myeloid leukaemia evaluating the effect on the incidence of major infection of a short-term ketogenic diet combined with 24-hour fasting compared to a standard hospital diet, before and during chemotherapy.
epean Blue Mountains Local Health District0 个研究点目标入组 134 人开始时间: 2020年8月27日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 134
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 75 Years(—)
- 性别
- All
入选标准
- •Participant is willing and able to give informed consent for participation in the trial.
- •Male or Female, aged 18-75 years.
- •Diagnosed with acute myeloid leukaemia.
- •Scheduled to undergo at least 4 or more cycles of chemotherapy
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- •Body mass index (BMI) > 21 kg/m^2
- •Weight loss < 5% of body weight in the last 6 months
- •Adequate renal function (serum creatinine < 1.5 X UNL [upper normal limit] or creatinine clearance > 50 ml/min)
- •Ability to complete patient booklet by themselves or with assistance
- •Ability and willingness to undergo short-term ketogenic diet combined with short term fasting prior to and during chemotherapy
排除标准
- •Pregnant women.
- •Nursing women.
- •Diabetes mellitus undergoing therapy with insulin or oral agents
- •History of low serum glucose (hypoglycaemia) or insulinoma
- •History of syncope with calorie restriction in the past or other medical comorbidity, which would make fasting potentially dangerous
- •History of significant cardiac disease, particularly uncompensated congestive heart failure New York Heart Association (NYHA) grade 2 or more or left ventricular ejection fraction (LVEF) < 40% on any prior assessment.
- •Psychiatric conditions that preclude adherence to study protocol
- •Patients receiving parenteral nutrition
- •Primary carnitine deficiency, carnitine palmitoyl transferase I or II deficiency, carnitine translocase deficiency, beta-oxidation defects, medium-chain acyl dehydrogenase deficiency, long-chain acyl dehydrogenase deficiency, short-chain acyl dehydrogenase deficiency, long-chain 3-hydroxyacyl-CoA deficiency, medium-chain 3-hydroxyacyl-CoA deficiency, pyruvate carboxylase deficiency, and porphyria.
研究者
相似试验
已完成
2 期
Continued use of Atorvostatin in sepsisSepsis / infection in patients taking statin therapyBlood - Studies of infection and infectious agentsACTRN12605000756628Dr Peter Kruger, Intensive Care Specialist, Princess Alexandra Hospital, Brisbane200
进行中(未招募)
2 期
ImmunoTACEHepacellular CarcinomaLiverCancerISRCTN11889464niversity of Birmingham (UK)48
进行中(未招募)
1 期
A study comparing the standard treatment of transarterial chemoembolisation (TACE)plus low doses of chemotherapy (cyclophosphamide) with an immune cell derived vaccineHepatocellular carcinomaEUCTR2011-001690-62-GBniversity of Birmingham48
招募中
2 期
An open, randomised, controlled phase II trial of CellProtect in combination with Isatuximab antibody versus Isatuximab antibody alone as maintenance treatment in patients with Multiple Myeloma undergoing high dose treatment (ISA-HC-NK)Multiple myeloma2024-514527-42-00Karolinska Institutet, Karolinska Institutet62
招募中
不适用
A Randomized Controlled Phase II Clinical Trial of Reconstruction method for the Elderly patients with gastric cancer after Distal Gastrectomy; Billroth-II Versus Roux-en-Y reconstructiogastric canerJPRN-UMIN000046950Clinical Study Group of Osaka University100
